A number of older retrospective studies (6, 35, 37) and more recent meta-analyses (38, 39) indicated that GH-treated patients with a history of intracranial tumor had lower rates of recurrence than untreated patients, but this likely reflects a selection bias, with those at a lower risk for tumor recurrence more likely to receive GH therapy. This evidence concerns the gene GH1 and neoplasm.